Kbt Medipharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -0.07%
- Profit Growth 84.44%
- Ebitda 154.42%
- Net Worth 5.38%
- Total Assets 41.55%
About Kbt Medipharma
Kbt Medipharma Private Limited (KMPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 September 2017 (Seven years and four months 21 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satender and Vidyanand Ojha serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC097143
-
Company No.
097143
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Sep 2017
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Kbt Medipharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satender
|
Director | 27-Dec-2022 | Current |
|
Vidyanand Ojha
|
Director | 27-Dec-2022 | Current |
Financial Performance of Kbt Medipharma.
Kbt Medipharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 0.07% decrease. The company also saw a substantial improvement in profitability, with a 84.44% increase in profit. The company's net worth moved up by a moderate rise of 5.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kbt Medipharma?
Unlock access to Kbt Medipharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Mudrika Infrabuilders And Developers Private LimitedSatender is a mutual person
-
Antiqe Planet Private Limited
Satender is a mutual person
-
Tv24 Univision Broadcast Private Limited
Vidyanand Ojha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kbt Medipharma?
Unlock and access historical data on people associated with Kbt Medipharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kbt Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kbt Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
